Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Health & Biotech
Health & Biotech
The world is one step closer to having a needle-free vaccine as Brisbane-based Vaxxas announced that it’s only three to five years away from releasing the product to the market.
Instead of syringes and needles, Vaxxas is working on a new, less invasive vaccine delivery technology that involves using patches called the Nanopatch.
The patch works by using thousands of tiny projections to deliver the vaccine just underneath the skin’s surface.
The small plastic patch is about 9 millimetres in diameter, and on the surface contains between 1,200 and 3,000 tiny nano-scale projections which feel like a nail file when you touch them.
They’re so small that one would need a scanning electron microscope to even look at the surface of the patch.
Those minuscule projections are coated with the vaccine, which then pierce the surface of the skin when applied for 10 seconds.
“It feels kind of like if you flick your arm with your nail,” Vaxxas’ head of medical device Michael Junger told ABC Radio Brisbane.
The technology has been used in other applications before like migraines, but it’s the first time it will be used to deliver a vaccine.
At the moment, Vaxxas said the plan is to use the technology to deliver vaccines for influenza, measles rubella, polio, and even COVID-19.
The company is racing to complete various clinical studies, with funding partly provided by the Gates Foundation.
Vaxxas has also just opened its custom-built, 5,500 square metre facility in Brisbane’s riverside suburb of Hamilton on Monday.
Backed by the Queensland government, the facility includes sterile clean rooms for manufacturing the vaccine patches, as well as laboratories and office space.
Deputy QLD Premier Steven Miles said the facility was a “game changer”.
“It’s testament to what’s possible here in Queensland now that we are truly a global biomedical hub,” Miles said.
“Next time there’s a pandemic, we’ll have access to vaccines first here locally.”
Volpara shares rose after signing a five-year SaaS contract with BreastScreen Victoria.
The contract is worth $1.4m in Total Contract Value (TCV), and includes Volpara Analytics, artificial intelligence (AI) quality software that assesses mammogram image for appropriate positioning, compression, and radiation dose.
BreastScreen Victoria is a public-screening programme in that diagnoses 37% of all breast cancers in Victoria.
Oneview rose as it entered into a reselling agreement with NYSE-listed Baxter International, one of the leading care communications providers in the world.
Under the deal, Baxter will resell Oneview’s Care Experience Platform (CXP) in the US market, including the CXP Cloud Enterprise.
Oneview had earlier advised the market that it was in advanced stages of signing an agreement with a major North American supplier of equipment to hospitals, which if signed may lead to additional sales of 3,000 to 5,000 beds per annum.
ONE says the deal with Baxter today is the agreement to which that update referred, and is considered material in the context of Oneview’s currently contracted book of approximately 15,000 beds.
Respri says it will acquire ACCESS telehealth, a leading US-based RPM provider for US$1.5m.
The acquisition means that Respiri will be first Australian company to deliver end-to-end RPM (remote patient monitoring) services to US health providers.
ACCESS is already a sales and marketing partner for Respiri’s wheezo device.
Respiri says the acquisition will now open up multiplies total addressable market, from 50m respiratory RPM patients to 150m+.
Telix announced that the first patient has been dosed in a Phase II study of the company’s carbonic anhydrase- (CAIX)-targeting PET/CT1 imaging agent TLX250-CDx.
CAIX is a protein over-expressed on the surface of clear cell renal cell carcinoma (ccRCC), the cancer target in Telix’s highly successful Phase III ZIRCON study.
Tumours that express CAIX are typically hypoxic, more aggressive and feature a tumour micro-environment (TME) that can be resistant to therapy, particularly immunotherapies.
The STARBURST study is exploring these tumour types in the refractory setting to assess whether tumour sites can be targeted, both for imaging and potentially therapeutic purpose.
Avecho has completed the development of its first edible dosage forms combining its TPM gummies with cannabinoids.
Avecho says TPM cannabinoid gummies out-perform standard products with faster onset and greater effect.
TPM cannabinoid gummies are also applicable to both medicinal and consumer cannabis markets.
With this new addition, Avecho’s portfolio of cannabinoid dosage forms now include oral oils, capsules, edibles, and topical gels.